Background: Poor breathing effort results in decrease oxygen supply to brain and other organs that lead to birth asphyxia. Phenobarbital and magnesium sulphate are both neuroprotective to asphyxia! injury to brain. Objective: To compare the frequency of neonatal mortality with phenobarbital versus magnesium sulphate in the management of birth asphyxia Study Design: Randomized control trial Place and Duration of Study: Pediatrics Department, Sheikh Zayed Hospital, from 8th March 2020 to 8th September 2020. Methodology: One hundred and two neonates were enrolled. After taking informed consent from parents their demographic data was obtained. Then patients were divided in to two groups; group A treated with Phenobarbital and other group B treated with magnesium sulphate. Results: The mean age of group A neonates was 54.37+14.303 days and in group B 48.40+15.20 days with male to female ratio was 0.7:1. Adverse outcome occurred in 12 (11.54%) patients. Statistically insignificant difference (P=0.122) was found between groups. Conclusion: There is more adverse effects outcome with magnesium sulphate than phenobarbital however the difference was statistically insignificant for management of neonates with birth asphyxia. Keywords: Birth asphyxia, Neonates, Magnesium sulphate (MgS04), Phenobarbital
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.